Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 143

1.

Pediatric microdose and microtracer studies using 14C in Europe.

Turner MA, Mooij MG, Vaes WH, Windhorst AD, Hendrikse NH, Knibbe CA, Kõrgvee LT, Maruszak W, Grynkiewicz G, Garner RC, Tibboel D, Park BK, de Wildt SN.

Clin Pharmacol Ther. 2015 Sep;98(3):234-7. doi: 10.1002/cpt.163. Epub 2015 Jul 17.

PMID:
26095095
2.

Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data.

Garner RC.

Bioanalysis. 2010 Mar;2(3):429-40. doi: 10.4155/bio.10.6. Review.

PMID:
21083253
3.

Accelerator mass spectrometry measurement of intracellular concentrations of active drug metabolites in human target cells in vivo.

Chen J, Garner RC, Lee LS, Seymour M, Fuchs EJ, Hubbard WC, Parsons TL, Pakes GE, Fletcher CV, Flexner C.

Clin Pharmacol Ther. 2010 Dec;88(6):796-800. doi: 10.1038/clpt.2010.188. Epub 2010 Oct 27.

PMID:
20981003
4.

Microdose pharmacokinetics of IDX899 and IDX989, candidate HIV-1 non-nucleoside reverse transcriptase inhibitors, following oral and intravenous administration in healthy male subjects.

Zhou XJ, Garner RC, Nicholson S, Kissling CJ, Mayers D.

J Clin Pharmacol. 2009 Dec;49(12):1408-16. doi: 10.1177/0091270009343698. Epub 2009 Sep 23.

PMID:
19776293
5.

A pharmacokinetic evaluation of five H(1) antagonists after an oral and intravenous microdose to human subjects.

Madan A, O'Brien Z, Wen J, O'Brien C, Farber RH, Beaton G, Crowe P, Oosterhuis B, Garner RC, Lappin G, Bozigian HP.

Br J Clin Pharmacol. 2009 Mar;67(3):288-98. doi: 10.1111/j.1365-2125.2008.03351.x.

6.

The utility of microdosing over the past 5 years.

Lappin G, Garner RC.

Expert Opin Drug Metab Toxicol. 2008 Dec;4(12):1499-506. doi: 10.1517/17425250802531767 . Review.

PMID:
19040326
7.

Safe sects? Dynamic religion and AIDS in South Africa.

Garner RC.

J Mod Afr Stud. 2000;38(1):41-69. No abstract available.

PMID:
18386417
8.

Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.

Beumer JH, Garner RC, Cohen MB, Galbraith S, Duncan GF, Griffin T, Beijnen JH, Schellens JH.

Invest New Drugs. 2007 Aug;25(4):327-34. Epub 2007 Mar 9.

9.

Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.

Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Oosterhuis B, Drijfhout WJ, Rowland M, Garner RC.

Clin Pharmacol Ther. 2006 Sep;80(3):203-15.

PMID:
16952487
10.

The use of accelerator mass spectrometry to obtain early human ADME/PK data.

Lappin G, Garner RC.

Expert Opin Drug Metab Toxicol. 2005 Jun;1(1):23-31. Review.

PMID:
16922650
11.

The use of isotopes in the determination of absolute bioavailability of drugs in humans.

Lappin G, Rowland M, Garner RC.

Expert Opin Drug Metab Toxicol. 2006 Jun;2(3):419-27. Review.

PMID:
16863443
12.

Determination of the bioavailability of [14C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers.

Klem B, Lappin G, Nicholson S, van de Wetering J, de Vries DE, Oosterhuis B, Garner RC.

J Clin Pharmacol. 2006 Apr;46(4):456-60.

PMID:
16554454
13.

Novel use of accelerator mass spectrometry for the quantification of low levels of systemic therapeutic recombinant protein.

Lappin G, Garner RC, Meyers T, Powell J, Varley P.

J Pharm Biomed Anal. 2006 Jun 16;41(4):1299-302. Epub 2006 Mar 22.

PMID:
16554138
14.

The phase 0 microdosing concept.

Garner RC, Lappin G.

Br J Clin Pharmacol. 2006 Apr;61(4):367-70. No abstract available.

16.

Less is more: the human microdosing concept.

Garner RC.

Drug Discov Today. 2005 Apr 1;10(7):449-51. No abstract available.

PMID:
15809185
17.

Vegetable, fruit and meat consumption and potential risk modifying genes in relation to colorectal cancer.

Turner F, Smith G, Sachse C, Lightfoot T, Garner RC, Wolf CR, Forman D, Bishop DT, Barrett JH.

Int J Cancer. 2004 Nov 1;112(2):259-64.

18.

The formation of AFB(1)-macromolecular adducts in rats and humans at dietary levels of exposure.

Cupid BC, Lightfoot TJ, Russell D, Gant SJ, Turner PC, Dingley KH, Curtis KD, Leveson SH, Turteltaub KW, Garner RC.

Food Chem Toxicol. 2004 Apr;42(4):559-69.

PMID:
15019179
19.

Tamoxifen DNA damage detected in human endometrium using accelerator mass spectrometry.

Martin EA, Brown K, Gaskell M, Al-Azzawi F, Garner RC, Boocock DJ, Mattock E, Pring DW, Dingley K, Turteltaub KW, Smith LL, White IN.

Cancer Res. 2003 Dec 1;63(23):8461-5.

20.

Current perspectives of 14C-isotope measurement in biomedical accelerator mass spectrometry.

Lappin G, Garner RC.

Anal Bioanal Chem. 2004 Jan;378(2):356-64. Epub 2003 Nov 18.

PMID:
14624324
21.

Sulforaphane and quercetin modulate PhIP-DNA adduct formation in human HepG2 cells and hepatocytes.

Bacon JR, Williamson G, Garner RC, Lappin G, Langouët S, Bao Y.

Carcinogenesis. 2003 Dec;24(12):1903-11. Epub 2003 Aug 29.

PMID:
12949046
22.

Early microdose drug studies in human volunteers can minimise animal testing: Proceedings of a workshop organised by Volunteers in Research and Testing.

Combes RD, Berridge T, Connelly J, Eve MD, Garner RC, Toon S, Wilcox P.

Eur J Pharm Sci. 2003 May;19(1):1-11.

PMID:
12729856
23.

Big physics, small doses: the use of AMS and PET in human microdosing of development drugs.

Lappin G, Garner RC.

Nat Rev Drug Discov. 2003 Mar;2(3):233-40. Review.

PMID:
12612650
24.

Investigation of interaction between N-acetyltransferase 2 and heterocyclic amines as potential risk factors for colorectal cancer.

Barrett JH, Smith G, Waxman R, Gooderham N, Lightfoot T, Garner RC, Augustsson K, Wolf CR, Bishop DT, Forman D; Colorectal Cancer Study Group.

Carcinogenesis. 2003 Feb;24(2):275-82.

PMID:
12584178
25.

Polymorphisms in the cytochrome P450 CYP1A2 gene (CYP1A2) in colorectal cancer patients and controls: allele frequencies, linkage disequilibrium and influence on caffeine metabolism.

Sachse C, Bhambra U, Smith G, Lightfoot TJ, Barrett JH, Scollay J, Garner RC, Boobis AR, Wolf CR, Gooderham NJ; Colorectal Cancer Study Group.

Br J Clin Pharmacol. 2003 Jan;55(1):68-76.

26.

Mutations in APC, Kirsten-ras, and p53--alternative genetic pathways to colorectal cancer.

Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, Garner RC, Steele RJ, Wolf CR.

Proc Natl Acad Sci U S A. 2002 Jul 9;99(14):9433-8. Epub 2002 Jul 1.

30.

A validation study comparing accelerator MS and liquid scintillation counting for analysis of 14C-labelled drugs in plasma, urine and faecal extracts.

Garner RC, Barker J, Flavell C, Garner JV, Whattam M, Young GC, Cussans N, Jezequel S, Leong D.

J Pharm Biomed Anal. 2000 Dec 15;24(2):197-209.

PMID:
11130199
31.
32.

Comparative biotransformation studies of MeIQx and PhIP in animal models and humans.

Garner RC, Lightfoot TJ, Cupid BC, Russell D, Coxhead JM, Kutschera W, Priller A, Rom W, Steier P, Alexander DJ, Leveson SH, Dingley KH, Mauthe RJ, Turteltaub KW.

Cancer Lett. 1999 Sep 1;143(2):161-5.

PMID:
10503897
33.

Macromolecular adduct formation and metabolism of heterocyclic amines in humans and rodents at low doses.

Turteltaub KW, Dingley KH, Curtis KD, Malfatti MA, Turesky RJ, Garner RC, Felton JS, Lang NP.

Cancer Lett. 1999 Sep 1;143(2):149-55.

PMID:
10503895
34.

Biomedical applications of accelerator mass spectrometry-isotope measurements at the level of the atom.

Barker J, Garner RC.

Rapid Commun Mass Spectrom. 1999;13(4):285-93. Review.

PMID:
10097404
35.

Comparison of DNA-adduct and tissue-available dose levels of MeIQx in human and rodent colon following administration of a very low dose.

Mauthe RJ, Dingley KH, Leveson SH, Freeman SP, Turesky RJ, Garner RC, Turteltaub KW.

Int J Cancer. 1999 Feb 9;80(4):539-45.

36.
37.

The role of DNA adducts in chemical carcinogenesis.

Garner RC.

Mutat Res. 1998 Jun 18;402(1-2):67-75. Review.

PMID:
9675247
38.

A preliminary evaluation of accelerator mass spectrometry in the biomedical field.

Kaye B, Garner RC, Mauthe RJ, Freeman SP, Turteltaub KW.

J Pharm Biomed Anal. 1997 Nov;16(3):541-3. No abstract available.

PMID:
9589415
39.

Metabolism of the food-borne mutagen 2-amino-3,8-dimethylimidazo[4,5-f]quinoxaline in humans.

Turesky RJ, Garner RC, Welti DH, Richoz J, Leveson SH, Dingley KH, Turteltaub KW, Fay LB.

Chem Res Toxicol. 1998 Mar;11(3):217-25.

PMID:
9544620
40.

A hot spot for p53 mutation in transitional cell carcinoma of the bladder: clues to the etiology of bladder cancer.

Xu X, Stower MJ, Reid IN, Garner RC, Burns PA.

Cancer Epidemiol Biomarkers Prev. 1997 Aug;6(8):611-6.

41.
42.

MeIQx-DNA adduct formation in rodent and human tissues at low doses.

Turteltaub KW, Mauthe RJ, Dingley KH, Vogel JS, Frantz CE, Garner RC, Shen N.

Mutat Res. 1997 May 12;376(1-2):243-52.

PMID:
9202761
43.

Biomonitoring of possible human exposure to environmental genotoxic chemicals: lessons from a study following the wreck of the oil tanker Braer.

Cole J, Beare DM, Waugh AP, Capulas E, Aldridge KE, Arlett CF, Green MH, Crum JE, Cox D, Garner RC, Dingley KH, Martin EA, Podmore K, Heydon R, Farmer PB.

Environ Mol Mutagen. 1997;30(2):97-111.

PMID:
9329634
44.

Molecular screening of multifocal transitional cell carcinoma of the bladder using p53 mutations as biomarkers.

Xu X, Stower MJ, Reid IN, Garner RC, Burns PA.

Clin Cancer Res. 1996 Oct;2(10):1795-800.

45.

Measurement of DNA adducts in humans after complex mixture exposure.

Dale CM, Garner RC.

Food Chem Toxicol. 1996 Sep;34(9):905-19. Review.

PMID:
8972883
46.
47.

Cyclophosphamide: review of its mutagenicity for an assessment of potential germ cell risks.

Anderson D, Bishop JB, Garner RC, Ostrosky-Wegman P, Selby PB.

Mutat Res. 1995 Aug;330(1-2):115-81. Review.

PMID:
7623863
48.

Molecular cancer epidemiology can predict risk.

Garner RC, Dingley K, Dale CM.

BMJ. 1995 Jan 14;310(6972):124-5. No abstract available.

49.

Low frequency and late occurrence of p53 and dcc aberrations in colorectal tumours.

Froggatt NJ, Leveson SH, Garner RC.

J Cancer Res Clin Oncol. 1995;121(1):7-15.

PMID:
7860623
50.

Effect of vitamin C upon gastric mucosal O6-alkyltransferase activity and on gastric vitamin C levels.

Dyke GW, Craven JL, Hall R, Garner RC.

Cancer Lett. 1994 Nov 11;86(2):159-65.

PMID:
7982203

Supplemental Content

Loading ...
Support Center